company background image
SCLP

Scancell HoldingsAIM:SCLP Stock Report

Market Cap

UK£165.1m

7D

0%

1Y

74.2%

Updated

30 Nov, 2021

Data

Company Financials +
SCLP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SCLP Stock Overview

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers.

Price History & Performance

Summary of all time highs, changes and price drops for Scancell Holdings
Historical stock prices
Current Share PriceUK£0.20
52 Week HighUK£0.28
52 Week LowUK£0.10
Beta0.098
1 Month Change2.53%
3 Month Change-10.99%
1 Year Change74.19%
3 Year Change161.29%
5 Year Change36.13%
Change since IPO563.93%

Recent News & Updates

Dec 28
Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Here's What Scancell Holdings plc's (LON:SCLP) Shareholder Ownership Structure Looks Like

Every investor in Scancell Holdings plc ( LON:SCLP ) should be aware of the most powerful shareholder groups...

Shareholder Returns

SCLPGB BiotechsGB Market
7D0%-2.4%-2.6%
1Y74.2%22.5%10.9%

Return vs Industry: SCLP exceeded the UK Biotechs industry which returned 24.4% over the past year.

Return vs Market: SCLP exceeded the UK Market which returned 13.8% over the past year.

Price Volatility

Is SCLP's price volatile compared to industry and market?
SCLP volatility
SCLP Average Weekly Movement4.7%
Biotechs Industry Average Movement5.9%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: SCLP is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: SCLP's weekly volatility has decreased from 11% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199722Lindy Durranthttps://www.scancell.co.uk

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company’s product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors.

Scancell Holdings Fundamentals Summary

How do Scancell Holdings's earnings and revenue compare to its market cap?
SCLP fundamental statistics
Market CapUK£165.08m
Earnings (TTM)-UK£15.48m
Revenue (TTM)n/a

0.0x

P/S Ratio

-10.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SCLP income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
ExpensesUK£15.48m
Earnings-UK£15.48m

Last Reported Earnings

Apr 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.019
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio77.9%

How did SCLP perform over the long term?

See historical performance and comparison

Valuation

Is Scancell Holdings undervalued compared to its fair value and its price relative to the market?

8.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SCLP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SCLP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SCLP is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.

PE vs Market: SCLP is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SCLP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCLP is overvalued based on its PB Ratio (8.5x) compared to the GB Biotechs industry average (6.3x).


Future Growth

How is Scancell Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

19.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SCLP's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if SCLP's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SCLP's revenue is forecast to grow faster than the UK market.

High Growth Revenue: SCLP is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SCLP's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Scancell Holdings performed over the past 5 years?

-27.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SCLP is currently unprofitable.

Growing Profit Margin: SCLP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SCLP is unprofitable, and losses have increased over the past 5 years at a rate of 27.4% per year.

Accelerating Growth: Unable to compare SCLP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCLP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).


Return on Equity

High ROE: SCLP has a negative Return on Equity (-79.43%), as it is currently unprofitable.


Financial Health

How is Scancell Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: SCLP's short term assets (£44.7M) exceed its short term liabilities (£2.3M).

Long Term Liabilities: SCLP's short term assets (£44.7M) exceed its long term liabilities (£27.3M).


Debt to Equity History and Analysis

Debt Level: SCLP has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SCLP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SCLP has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SCLP has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 17.7% each year


Dividend

What is Scancell Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SCLP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SCLP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SCLP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCLP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCLP's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Lindy Durrant

0.33

Tenure

UK£201,250

Compensation

Prof. Lindy Gillian Durrant, Ph D., has been the Chief Executive Officer of Scancell Holdings plc since July 28, 2021. She is the Founder of Scancell Holdings PLC and serves as its Chief Scientific Officer...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Lindy's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Lindy's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SCLP's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: SCLP's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Scancell Holdings plc's employee growth, exchange listings and data sources


Key Information

  • Name: Scancell Holdings plc
  • Ticker: SCLP
  • Exchange: AIM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£165.082m
  • Shares outstanding: 815.22m
  • Website: https://www.scancell.co.uk

Number of Employees


Location

  • Scancell Holdings plc
  • John Eccles House
  • Robert Robinson Avenue
  • Oxford
  • Oxfordshire
  • OX4 4GP
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 21:35
End of Day Share Price2021/11/30 00:00
Earnings2021/04/30
Annual Earnings2021/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.